Mahmoud Omar

ORCID: 0009-0000-7512-5922
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Thyroid Cancer Diagnosis and Treatment
  • Thyroid and Parathyroid Surgery
  • COVID-19 Clinical Research Studies
  • COVID-19 and healthcare impacts
  • Gastric Cancer Management and Outcomes
  • Neuroendocrine Tumor Research Advances
  • Long-Term Effects of COVID-19
  • Head and Neck Anomalies
  • Esophageal Cancer Research and Treatment
  • Respiratory Support and Mechanisms
  • Biomarkers in Disease Mechanisms
  • Cardiac, Anesthesia and Surgical Outcomes
  • Inflammatory Bowel Disease
  • Pituitary Gland Disorders and Treatments
  • Thyroid Disorders and Treatments
  • Parathyroid Disorders and Treatments
  • Tracheal and airway disorders
  • Intensive Care Unit Cognitive Disorders
  • Urticaria and Related Conditions
  • Mast cells and histamine
  • Gastrointestinal Tumor Research and Treatment
  • S100 Proteins and Annexins
  • Diabetes Treatment and Management
  • Genetic Syndromes and Imprinting
  • Adrenal and Paraganglionic Tumors

Tulane University
2020-2025

Assiut University
2025

National Institute for Health Research
2024

University of Birmingham
2021-2024

Tanta University
2023

Yale University
2023

NIHR Birmingham Biomedical Research Centre
2021

Yorkshire Cancer Research
2021

Urology Foundation
2021

Association for Cancer Surgery
2021

<b>Background and aim: </b>This Guideline is an official statement of the European Society Gastrointestinal Endoscopy (ESGE). It addresses choice amongst regimens available for cleansing colon in preparation colonoscopy. <b>Methods:</b> This based on a targeted literature search to evaluate evidence supporting use bowel The Grading Recommendations Assessment, Development Evaluation (GRADE) system was adopted define strength recommendation quality evidence. <b>Results:</b> main...

10.1055/s-0032-1326186 article EN Endoscopy 2013-01-18

Many countries in Europe are now introducing screening for colorectal cancer [1]. This considerable investment adds to national economic burdens and must be audited demonstrate that it is cost-effective, well-targeted of high quality. Spending more money, having doctors, admitting patients or a nearby "center excellence" does not necessarily result improved outcomes.

10.1055/s-0032-1325686 article EN Endoscopy 2012-09-17

Background: Radiofrequency ablation (RFA) has been recently adopted into the practice of thyroidology in United States, although its use as an alternative to traditional thyroid surgery Asia and Europe came near turn 21st century. In only a few studies with small sample sizes have published date. We examined outcomes benign nodules treated RFA from 2 North American institutions. Methods: performed prospective, multi-institutional cohort study between July 2019 January 2022. Demographics,...

10.1097/sla.0000000000005594 article EN Annals of Surgery 2022-07-15

Background: We sought to investigate the outcomes associated with COVID-19 disease in cancer patients. Methods: conducted a retrospective cohort study of laboratory-confirmed Results: Of 206 patients included, 57 had at least one preexisting malignancy. Cancer were older than noncancer 185 discharged cases, significantly higher frequency unplanned reintubation (7.1% vs 0.9%, p < 0.049), and required longer hospital stay (8.58 ± 6.50 days versus 12.83 11.44 days, 0.002). Regression analysis...

10.2217/fon-2021-0121 article EN Future Oncology 2021-07-15

Inflammatory bowel disease (IBD) is emerging in the newly industrialized countries of South Asia, South-East and Middle East, yet epidemiological data are scarce.We performed a cross-sectional study IBD demographics, phenotype, treatment across 38 centers 15 East. Intergroup comparisons included gross national income (GNI) per capita.Among 10 400 patients, ulcerative colitis (UC) was twice as common Crohn's (CD), with male predominance (UC 6678, CD 3495, unclassified 227, 58% male). Peak age...

10.1111/jgh.15801 article EN Journal of Gastroenterology and Hepatology 2022-02-17

Thyroid nodules can be classified as benign, malignant, or indeterminate, the latter of which make up 10–30% nodules. Radiofrequency ablation (RFA) has become an attractive and promising therapy for treatment benign thyroid However, few studies have investigated safety efficacy RFA management indeterminate In this study, 178 patients with diagnosed (Bethesda II) III/IV) by preoperative cytopathological analysis were included. Patients in cohorts had similar nodule volume reduction rates at...

10.3390/ijms231911493 article EN International Journal of Molecular Sciences 2022-09-29

Hashimoto's thyroiditis (HT) (autoimmune thyroiditis) is a clinicopathological entity associated with chronic lymphocytic infiltration resulting in hypothyroidism. HT double-edged sword that increases the risk of papillary thyroid cancer (PTC), yet it serves as protective factor for PTC progression. BRAF mutation PTCs rapid cell growth, aggressive tumor characteristics, and higher mortality rates. Here, we aimed to analyze influence patients its effect on lymph node metastasis (LNM) mutant...

10.3390/biomedicines10082051 article EN cc-by Biomedicines 2022-08-22

Due to the paucity of data and controversy regarding preferred surgical approach for managing tertiary HPT, we sought investigate outcomes different approaches in this challenging disease.We performed a multi-center retrospective study include patients with HPT who underwent STPX or total parathyroidectomy autotransplantation (TPX-A).One hundred five had kidney transplant, 43 were on dialysis. In transplant group, 61 STPX, 44 TPX-A. Patients' demographics not significantly (48.61 ± 9.31 vs...

10.1097/sla.0000000000005059 article EN Annals of Surgery 2021-07-12

Indeterminate thyroid nodules (ITN) represent 20–30% of biopsied nodules, with a 10–60% risk malignancy. Molecular testing can stratify the malignancy among ITNs, and subsequently reduce need for unnecessary diagnostic surgery. We aimed to assess performance these molecular tests at single institution. Patients Bethesda III, IV, V Afirma Interpace Diagnostics genetic data from November 2013 2021 were included. Three cohorts formed, including GSC + XA, ThyGeNEXT ThyraMIR, GEC. Statistical...

10.3390/cancers15072098 article EN Cancers 2023-03-31
Coming Soon ...